Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan

Pharmacogenomics Journal

Volumn 10, Issue 5, 2010, Pages 458-464

  Graziano, F ^a   Canestrari, E ^b   Loupakis, F ^c   Ruzzo, A ^b   Galluccio, N ^b   Santini, D ^d   Rocchi, M ^b   Vincenzi, B ^d   Salvatore, L ^c   Cremolini, C ^c   Spoto, C ^d   Catalano, V ^a   D'Emidio, S ^a   Giordani, P ^a   Tonini, G ^d   Falcone, A ^c   Magnani, M ^b  

^a SAN SALVATORE HOSPITAL   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

cetuximab; colorectal cancer; KRAS; Let 7; microRNA; polymorphism

Indexed keywords

B RAF KINASE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN; MICRORNA;

3' UNTRANSLATED REGION; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC REGULATION; GENOTYPE; HETEROZYGOTE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RNA BINDING; WILD TYPE;

3' UNTRANSLATED REGIONS; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 77957145245     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.9     Document Type: Article

References (29)

1. Ambros V. The evolution of our thinking about microRNAs. Nat Med 2008; 14: 1036-1040.
2. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009; 174: 1131-1138.
3. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27: 5959-5974.
4. Lee YH, Dutta A. MicroRNAs: small but potent oncogenes or tumor suppressors. Curr Opin Investig Drugs 2006; 7: 560-564.
5. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol 2008; 18: 505-516.
6. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647.
7. Jérôme T, Laurie P, Louis B, Pierre C. Enjoy the silence: the story of let-7 microRNA and cancer. Curr Genomics 2007; 8: 229-233.
8. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-7722.
9. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008; 105: 3903-3908.
10. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006; 29: 903-906.
11. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009; 10: 399-416.
12. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I et al. A SNP in a let-7 microRNA complementary site in the KRAS 3 untranslated region increases non-small cell lung cancer risk. Cancer Res 2008; 68: 8535-8540.
13. Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza S, McClean MD et al. A let-7 microRNA binding site polymorphism in the KRAS 3 UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009; 30: 1003-1007.
14. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
15. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
16. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
17. Osier MV, Cheung KH, Kidd JR, Pakstis AJ, Miller PL, Kidd KK. ALFRED: an allele frequency database for diverse populations and DNA polymorphisms\an update. Nucleic Acids Res 2001; 29: 317-319.
18. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007; 104: 11400-11405.
19. Ding XC, Slack FJ, Grosshans H. The let-7 microRNA interfaces extensively with the translation machinery to regulate cell differentiation. Cell Cycle 2008; 7: 3083-3090.
20. Torrisani J, Bournet B, Chalret du Rieu M, Bouisson M, Souque A, Escourrou J et al. Let-7 microRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009; 20: 831-844.
21. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008; 7: 759-764.
22. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123.
23. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756.
24. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs\the micro steering wheel of tumour metastases. Nat Rev Cancer 2009; 9: 293-302.
25. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009; 10: 578-585.
26. Tsang WP, Kwok TT. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009; 30: 953-959.
27. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-1392.
28. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67: 11111-11116.
29. Li Y, VandenBoom II TG, Kong D, Wang Z, Ali S, Philip PA et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.